Emerging From Stealth Mode, Tesselate Bio Looks To Develop Next-Gen Synthetic Lethality Drugs

 
• By Andrew McConaghie

As investment and interest grows in synthetic lethality cancer treatments, Netherlands-headquartered Tesselate Bio hopes to expand horizons within the field by hitting the novel FANCM target and developing its own companion diagnostic.

Zuidas, Amsterdam
The new biotech has been set up with funding from BioGeneration Ventures and Forbion and is headquartered just outside Amsterdam, Netherlands.

More from Start-Ups & SMEs

More from Business